Simplify Asset Management Inc. Has $1.81 Million Stake in Fulcrum Therapeutics, Inc. $FULC

Simplify Asset Management Inc. increased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 91.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,674 shares of the company’s stock after buying an additional 76,440 shares during the period. Simplify Asset Management Inc. owned 0.30% of Fulcrum Therapeutics worth $1,806,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Aberdeen Group plc raised its position in shares of Fulcrum Therapeutics by 135.0% in the third quarter. Aberdeen Group plc now owns 137,961 shares of the company’s stock valued at $1,269,000 after buying an additional 79,265 shares in the last quarter. Braidwell LP acquired a new stake in shares of Fulcrum Therapeutics in the third quarter valued at approximately $2,019,000. Boothbay Fund Management LLC raised its position in Fulcrum Therapeutics by 104.2% during the third quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock valued at $6,241,000 after purchasing an additional 346,136 shares in the last quarter. Suvretta Capital Management LLC raised its position in Fulcrum Therapeutics by 5.9% during the third quarter. Suvretta Capital Management LLC now owns 5,381,000 shares of the company’s stock valued at $49,505,000 after purchasing an additional 298,100 shares in the last quarter. Finally, GSA Capital Partners LLP raised its position in Fulcrum Therapeutics by 256.4% during the third quarter. GSA Capital Partners LLP now owns 116,068 shares of the company’s stock valued at $1,068,000 after purchasing an additional 83,505 shares in the last quarter. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ:FULC opened at $6.57 on Monday. The company has a fifty day moving average of $7.31 and a 200-day moving average of $9.27. The company has a market capitalization of $437.76 million, a PE ratio of -5.71 and a beta of 3.02. Fulcrum Therapeutics, Inc. has a 52-week low of $5.88 and a 52-week high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.06. On average, equities analysts forecast that Fulcrum Therapeutics, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on FULC. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. Leerink Partners restated an “outperform” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Finally, Truist Financial set a $17.00 price objective on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Fulcrum Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.